SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-038854
Filing Date
2024-04-01
Accepted
2024-04-01 06:30:12
Documents
12
Period of Report
2024-04-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aktx-20240401.htm   iXBRL 8-K 46026
2 EX-99.1 aktx-ex99_1.htm EX-99.1 87875
  Complete submission text file 0000950170-24-038854.txt   365179

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT aktx-20240401.xsd EX-101.SCH 97461
15 EXTRACTED XBRL INSTANCE DOCUMENT aktx-20240401_htm.xml XML 6056
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

IRS No.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 24805443
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)